Iñaki Paris

This study shows that long-term anti-Aβ treatment reduces amyloid plaques and microglial activation but leaves residual plaques with persistent immune activity.

The paper identifies two compounds, trifluoperazine and deoxytubercidin, as novel microglial phagocytosis inhibitors using high-throughput screening and in vivo validation.

Peripheral AAV-mediated delivery of brain-penetrant PGRN rescues TDP-43 pathology, neurodegeneration and motor phenotypes in FTLD-GRN models.